Elevated peripheral visfatin levels in narcoleptic patients

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Dahmen, Norbert ^a   Manderscheid, Nina ^a   Helfrich, Jana ^a   Musholt, Petra B ^b   Forst, Thomas ^b   Pfützner, Andreas ^b   Engel, Alice ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b IKFE GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR2 ANTIGEN; VISFATIN; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; PROTEIN BLOOD LEVEL; STRUCTURED INTERVIEW; SYMPTOMATOLOGY; UNSTRUCTURED INTERVIEW; BLOOD; ENZYMOLOGY; MIDDLE AGED; ONSET AGE; POLYSOMNOGRAPHY; REFERENCE VALUE;

ADULT; AGE OF ONSET; AGED; BODY MASS INDEX; CYTOKINES; FEMALE; HLA-DR2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYSOMNOGRAPHY; REFERENCE VALUES;

EID: 52149097570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002980     Document Type: Article

References (41)

1. Aldrich MS (1990) Narcolepsy. N Engl J Med 323: 389-394.
2. Dahmen N, Bierbrauer J, Kasten M (2001) Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 251(2): 85-9.
3. Schuld A, Hebebrand J, Geller F, Pollmächer T (2000) Increased body-mass index in patients with narcolepsy. Lancet 355(9211): 1274-5.
4. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
5. Lin L, Faraco J, Li R, Kadotani H, Rogers W, et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365-376.
6. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355: 39-40.
7. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, et al. (2001) Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50(3): 381-8.
8. Higuchi S, Usui A, Murasaki M, Matsushita S, Nishioka N, et al. (2002) Plasma orexin-A is lower in patients with narcolepsy. Neurosci Lett 318(2): 61-4.
9. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C (1997) HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20(11): 1012-20.
10. Rogers AE, Meehan J, Guilleminault C, Grumet FC, Mignot E (1997) HLA DR15 (DR2) arid DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 48(6): 1550-6.
11. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56(6): 905-8
12. Black JL 3rd (2005) Narcolepsy: a review of evidence for autoimmune diathesis. Int Rev Psychiatry 17(6): 461-9.
13. Martínez-Rodríguez JE, Iranzo A, Casamitjana I, Graus F, Santamaria J (2007) Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia. Med Clin (Barc) 128(10): 361-4.
14. Vgontzas AN, Chrousos GP (2002) Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 31(1): 15-36.
15. Hinze-Selch D, Wetter TC, Zhang Y, Lu HC, Albert ED, et al. (1998) In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 50(4): 1149-52.
16. Okun ML, Giese S, Lin L, Einen M, Mignot E, et al. (2004) Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun 18(4): 326-32.
17. Himmerich H, Beitinger PA, Fulda S, Wehrle R, Linseisen J, et al. (2006) Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. Arch Intern Med 166(16): 1739-43.
18. Hohjoh H, Terada N, Kawashima M, Honda Y, Tokunaga K (2000) Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens, 56(5): 446-8.
19. Hohjoh H, Nakayama T, Ohashi J, Miyagawa T, Tanaka H, et al. (1999) Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 54(2): 138-45.
20. Wieczorek S, Gencik M, Rujescu D, Tonn P, Giegling I, et al. (2003) TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 61(6): 437-42.
21. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708): 426-30. Retracted by the authors (2007) Science 318: 565..
22. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748-58.
23. Rajala MW, Scherer PE (2003) Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144: 3765-73.
24. Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immumol 6(10): 772-83.
25. Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, et al. (2007) Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk-Results from the PIOSTAT Study. Horm Metab Res 39: 764-768.
26. Thorpy MJ (1990) ICSD - International classification of sleep disorders: Diagnostic and coding manual. Diagnostic Classification Steering Committee. American Sleep Disorders Association: Rochester, Minnesota.
27. Mignot E, Tafti M, Dement WC, Grumet FC (1995) Narcolepsy and immunity. Adv Neuroimmunol 5(1): 23-37.
28. Hector J, Schwarloh B, Goehring J, Strate TG, Hess UF, et al, (2007) TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39(4): 250-5.
29. Wurtmann RJ (2006) Narcolepsy and the hypocretins. Metabolism 55(10 Suppl 2): 36-S39.
30. Otero M, Lago R, Gomez R, Lago F, Dieguez C, et al. (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 64: 1198-1201.
31. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, et al. (2006) Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55(10): 2871-5.
32. Pilz S, Mangge H, Obermayer-Pietsch B, März W (2007) Visfatin/ pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 30(2): 138-44.
33. Guzik TJ, Mangalat D, Korbut R (2006) Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 57(4): 505-28.
34. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, et al. (2002)The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59(10): 1553-62.
35. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54(10): 2911-6.
36. Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, et al. (2007) Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 21(2): 173-5.
37. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, et al. (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76(1): 24-9.
38. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, et al. (2007) Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol, Metab 92(2): 666-72.
39. Marcinkowska M, Lewandowski KC, Lewiński A, Bieńkiewicz M, Basińska-Lewandowska M, et al. (2007) Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans. Endokrynol Pol 58(3): 188-94.
40. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, et al. (2007) Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 88(2): 401-5.
41. Dauvilliers Y, Neidhart E, Lecendreux M, Billiard M, Tafti M (2001) MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry. 6(4): 367-72.